Life Diagnostics

Executive Summary

Life Diagnostics, Inc. is a privately held US-based manufacturer of specialized research reagents and diagnostic kits for preclinical and veterinary research. Founded in 2003 and headquartered in West Chester, Pennsylvania, the company produces ELISA kits, SPARCL kits, antibodies, and purified proteins targeting biomarkers in cardiology, immunotoxicity, acute phase response, and skeletal muscle injury. Its products serve a broad range of species used in biomedical research and veterinary medicine. Despite a focused product portfolio and a niche in the research reagent market, Life Diagnostics operates in a pre-clinical stage with limited public information on financial performance or commercial traction. The company has not disclosed funding rounds or valuation, and its profile on research databases shows low completeness, indicating limited external visibility. As a small player in the competitive antibody and kit manufacturing space, Life Diagnostics faces challenges in scaling and differentiation. However, its long history since 2003 suggests operational stability. Conviction in the company as an investment opportunity is moderate, given the lack of transparent growth metrics or near-term value inflection points.

Upcoming Catalysts (preview)

• Q4 2026Launch of Novel Veterinary Diagnostic Kits50% success
• Q2 2027Strategic Partnership with Pharmaceutical CRO40% success
• Q1 2027Expansion into Companion Animal Diagnostics Market35% success